Introduction
Ischemic stroke remains a leading cause of mortality and long-term disability worldwide. While the restoration of blood flow—reperfusion—is essential for clinical recovery, it often triggers a secondary cascade of damage known as cerebral ischemia-reperfusion (CI/R) injury. This pathological process is characterized by a complex interplay of oxidative stress, massive neuroinflammation, and widespread neuronal apoptosis. Despite extensive research, many neuroprotective agents have failed in clinical translation, highlighting the need for multi-targeted therapeutic strategies.
Alisol A 24-acetate (24A), a triterpenoid derived from the traditional medicinal plant Alisma Orientale, has previously demonstrated potent anti-inflammatory properties in liver disease models. This study investigates the neuroprotective potential of 24A in a mouse model of global cerebral ischemia-reperfusion (GCI/R) injury, focusing on its ability to modulate the PI3K/AKT signaling pathway.
Experimental Design and Methodology
To simulate global cerebral ischemia, researchers utilized a 2-VO (bilateral common carotid artery occlusion) model in male C57BL/6J mice. The animals were subjected to 20 minutes of ischemia followed by reperfusion. The experimental groups included a Sham group, a GCI/R group, a GCI/R+24A treatment group (30 mg/kg), and a group receiving both 24A and the PI3K inhibitor LY294002 to validate the mechanism of action.
Functional recovery was assessed using modified neurological deficit scores (mNSS), the Morris Water Maze (MWM) for spatial memory, and Novel Object Recognition (NOR) tests. Additionally, in vivo Magnetic Resonance Spectroscopy (MRS) was employed to monitor metabolic changes in specific brain regions, including levels of N-acetylaspartate (NAA), glutamate/glutamine (Glx), and Taurine.
Results
Functional and Metabolic Recovery
Treatment with 24A significantly improved behavioral outcomes following GCI/R injury. Mice in the 24A group exhibited lower mNSS scores and enhanced performance in the MWM and NOR tests compared to untreated GCI/R mice ($p < 0.05$). MRS analysis revealed that 24A treatment effectively reversed metabolic dysregulation; specifically, it restored levels of NAA (a marker of neuronal integrity) and reduced the pathological elevation of Glx and Taurine. These findings suggest that 24A preserves neuronal health at both a functional and biochemical level.
Mitigation of Neuroinflammation and Apoptosis
At the cellular level, 24A demonstrated a robust ability to suppress the activation of microglia (Iba1+) and astrocytes (GFAP+), thereby reducing the hyper-inflammatory state that typically follows reperfusion. This was accompanied by a significant decrease in pro-inflammatory cytokines, including IL-1β, TNF-α, and iNOS ($p < 0.01$ or $p < 0.05$).
Furthermore, 24A exerted strong anti-apoptotic effects. Golgi staining showed that 24A preserved dendritic spine density in the hippocampus and cortex, which is critical for cognitive function. Molecular analysis confirmed that 24A shifted the Bax/Bcl-2 ratio toward cell survival and significantly downregulated the expression of cleaved Caspase-3, a key executioner of programmed cell death.
Activation of the PI3K/AKT Pathway
The study identified the PI3K/AKT signaling pathway as the primary mediator of 24A’s neuroprotective effects. 24A acted as an agonist, increasing the phosphorylation of PI3K and AKT. When the PI3K inhibitor LY294002 was administered, the beneficial effects of 24A on inflammation, apoptosis, and behavioral recovery were largely abolished. This confirms that 24A protects the brain by activating this master regulator of cell survival.
Conclusion
This study demonstrates that Alisol A 24-acetate (24A) provides significant neuroprotection against GCI/R injury by suppressing neuroinflammation and apoptosis via the PI3K/AKT pathway. By improving both metabolic stability and synaptic plasticity, 24A represents a promising multi-targeted candidate for the treatment of ischemic stroke. Future research should explore its efficacy in focal ischemia models and determine the optimal therapeutic window for clinical application.
Summary updated